Company news

Indivior Pharmaceuticals, Inc. news in 2024

Indivior Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

October 29, 2024

Indivior Announces Q3 2024 Financial Results

October 23, 2024

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

October 9, 2024

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

October 6, 2024

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

September 3, 2024

Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness

August 25, 2024

Indivior Announces Q2 2024 Financial Results

July 24, 2024

Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame

July 24, 2024

Indivior Provides Business Update; Conference Call at 8: 00 AM U.S. EDT

July 8, 2024

Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression an...

June 17, 2024

Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder

June 9, 2024

Indivior Announces Q1 2024 Financial Results

April 24, 2024

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

March 10, 2024

Indivior Announces Q4 / FY 2023 Financial Results

February 21, 2024

Calls in 2024

Decks in 2024